U.K. biotech Immunocore has reported an estimated 70% two-year survival rate among 17 evaluable first-line metastatic uveal ...

Dutch-Belgian immunology company argenx has agreed to acquire California-based Unnatural Products Inc. (UNP) for up to $1.15 ...

Gene therapies began as proof-of-concept treatments for a handful of rare genetic disorders and now, with emerging tools, may ...

University of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting ...

Nine reports of tumors in children treated with Novartis' spinal muscular atrophy (SMA) gene therapy Zolgensma raise new ...

The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report ...

Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical ...

French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business.

Dutch biotech Anaheim Bio, a spin-out of BioMarin-acquired Alesta Therapeutics, has launched with an oversubscribed €40 ...

Switzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits ...

As advanced therapies and vaccines reshape healthcare, Wacker ­Biotech is emerging as a CDMO partner of choice. With decades ...

Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions ...